Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > April 22, 2020
Daily News
April 22, 2020
- Japan Heading into Earnings Season amid Coronavirus Woes
April 22, 2020
- Shin Nippon Biomedical Joins AnGes Vaccine Development
April 22, 2020
- Drug Makers Restricting Nafamostat Supplies as Hopes Grow for Its Repurposing for COVID-19
April 22, 2020
- Drug Rep Number Might Have Logged 5,000-Plus Decrease in 1 Year: Jiho Tally
April 22, 2020
- Ehime Univ., Sumitomo Dainippon Decipher Mechanism of Action of Malaria Vaccine Candidate
April 22, 2020
- Positive Data in Hand, Ono/Takeda to Seek 1st-Line RCC Nod for Opdivo/Cabometyx Combo
April 22, 2020
- Japan to Make Drug Review Time as Short as Possible for COVID-19: Minister
April 22, 2020
- Astellas Scoops Up UK's Mitochondria-Focused Biotech Nanna
April 22, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…